Cyclooxygenase(COX)-2-inhibition in the prevention and treatment of colorectal carcinoma;Cyclo-oxygenase(COX)-2-remming bij de preventie en de behandeling van colorectaal carcinoom

Nederlands Tijdschrift voor Geneeskunde

Volumn 147, Issue 45, 2003, Pages 2207-2212

  Tuynman, J B ^a,b   Hulscher, J B F ^a   Steller, E Ph ^a   Van Lanschot, J J B ^b   Richel, D J ^b  

^a ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; APC PROTEIN; CELECOXIB; CISPLATIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; FLUOROURACIL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTACYCLIN; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN F; SULINDAC; THROMBOXANE A2; TILMACOXIB; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; ARTHRITIS; CANCER PREVENTION; CANCER RISK; CELL PROLIFERATION; CHRONIC DISEASE; CLINICAL TRIAL; COLON POLYPOSIS; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG USE; FAMILIAL COLON POLYPOSIS; FAMILY HISTORY; GASTROINTESTINAL TOXICITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LONG TERM CARE; PHASE 3 CLINICAL TRIAL; PROSTAGLANDIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ADENOMA; ADENOMATOUS POLYPOSIS COLI; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; NEOPLASM METASTASIS; PROGNOSIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; TREATMENT OUTCOME;

EID: 0242544045     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Visser O, Coebergh JWW, Dijck JAAM van, Siesling S, editors. Incidence of cancer in the Netherlands 1998. Amsterdam: Vereniging van Integrale Kankercentra; 2002.
2. Woodman CB, Gibbs A, Scott N, Haboubi NY, Collins S. Are differences in stage at presentation a credible explanation for reported differences in the survival of patients with colorectal cancer in Europe? Br J Cancer 2001;85:787-90.
3. Jessup JM, Stewart AK, Menck HR. The National Cancer Data Base report on patterns of care for adenocarcinoma of the rectum, 1985-95. Cancer 1998;83:2408-18.
4. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995;122:321-6.
5. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345:638-46.
6. Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307-11.
7. Suh O, Mettlin C, Petrelli NJ. Aspirin use, cancer, and polyps of the large bowel. Cancer 1993;72:1171-7.
8. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994;121:241-6.
9. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333:609-14.
10. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994; 5:138-46.
11. Thun MJ, Namboodiri MM, Heath jr CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593-6.
12. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of antiinflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000;320:1642-6.
13. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252-66.
14. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996;271: 33157-60.
15. Hudson N, Hawthorne AB, Cole AT, Jones PD, Hawkey CJ. Mechanisms of gastric and duodenal damage and protection. Hepatogastroenterology 1992;39 Suppl 1:31-6.
16. Dogne JM, de Leval X, Delarge J, David JL, Masereel B. New trends in thromboxane and prostacyclin modulators. Curr Med Chem 2000; 7:609-28.
17. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-17.
18. Lems WF, Laar MAFJ van de, Bijlsma JWJ. Veiligheid van specifieke cyclo-oxygenase-2-remmers. Ned Tijdschr Geneeskd 2001;145: 1044-7.
19. Bijlsma JWJ, Putte LBA van de. Niet-steroïde anti-inflammatoire medicijnen (NSAID's) met minder bijwerkingen door selectieve remming van cyclo-oxygenase-2. Ned Tijdschr Geneeskd 1998;142: 1762-5.
20. Chen CC, Sun YT, Chen JJ, Chiu KT. TNF-alpha-induced cyclooxygenase-2 expression in human lung epithelial cells: involvement of the phospholipase C-gamma 2, protein kinase C-alpha, tyrosine kinase, NF-kappa B-inducing kinase, and I-kappa B kinase 1/2 pathway. J Immunol 2000;165:2719-28.
21. Tomozawa S, Tsuno NH, Sunami E, Hatano K, Kitayama J, Osada T, et al. Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer 2000;83:324-8.
22. Rees BP van, Saukkonen K, Ristimaki A, Polkowski W, Tytgat GN, Drillenburg P, et al. Cyclooxygenase-2 expression during carcinogenesis in the human stomach. J Pathol 2002;196:171-9.
23. Buskens CJ, Rees BP van, Sivula A, Reitsma JB, Haglund C, Bosma PJ, et al. Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 2002;122:1800-7.
24. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002;62:632-5.
25. Yoshimura R, Sano H, Mitsuhashi M, Kohno M, Chargui J, Wada S. Expression of cyclooxygenase-2 in patients with bladder carcinoma. J Urol 2001;165:1468-72.
26. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998;58:4997-5001.
27. Yoshimura R, Sano H, Masuda C, Kawamura M, Tsubouchi Y, Chargui J, et al. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 2000;89:589-96.
28. Ferrandina G, Lauriola L, Zannoni GF, Distefano MG, Legge F, Salutari V, et al. Expression of cyclooxygenase-2 (COX-2) in tumour and stroma compartments in cervical cancer: clinical implications. Br J Cancer 2002;87:1145-52.
29. Zielinski CC, Gisinger C, Binder C, Mannhalter JW, Eibl MM. Regulation of NK cell activity by prostaglandin E2: the role of T cells. Cell Immunol 1984;87:65-72.
30. Igarashi K, Woo JT, Stern PH. Effects of a selective cyclooxygenase-2 inhibitor, celecoxib, on bone resorption and osteoclastogenesis in vitro. Biochem Pharmacol 2002;63:523-32.
31. McCarthy D. Nonsteroidal anti-inflammatory drug-related gastrointestinal toxicity: definitions and epidemiology. Am J Med 1998; 105:3S-9S.
32. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study. A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55.
33. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8.
34. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 2002;325:619-23.
35. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.
36. Zhang H, Sun XF. Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. Am J Gastroenterol 2002; 97:1037-41.
37. Luijt RB van der, Tops CMJ, Vasen HFA. Van gen naar ziekte; het APC-gen en familiaire adenomateuze polyposis. Ned Tijdschr Geneeskd 2000;144:2007-9.
38. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997;275:1787-90.
39. Dihlmann S, Siermann A, von Knebel, Doeberitz M. The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling. Oncogene 2001;20:645-53.
40. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-16.
41. Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001;15:2742-4.
42. Specht C, Bexten S, Kolsch E, Pauels HG. Prostaglandins, but not tumor-derived IL-10, shut down concomitant tumor-specific CTL responses during murine plasmacytoma progression. Int J Cancer 2001;91:705-12.
43. Wagenaar-Miller RA, Hanley G, Shattuck-Brandt R, DuBois RN, Bell RL, et al. Cooperative effects of matrix metalloproteinase and cyclooxygenase-2 inhibition on intestinal adenoma reduction. Br J Cancer 2003;88:1445-52.
44. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87:803-9.
45. Ladabaum U, Chopra CL, Huang G, Scheiman JM, Chernew ME, Fendrick AM. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis. Ann Intern Med 2001;135:769-81.
46. Suleiman S, Rex DK, Sonnenberg A. Chemoprevention of colorectal cancer by aspirin: a cost-effectiveness analysis. Gastroenterology 2002;122:78-84.
47. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9.
48. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328:1313-6.
49. Giardiello FM, Yang VW, Hylind LM, Krush AJ, Petersen GM, Trimbath JD, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 2002;346:1054-9.
50. Cruz-Correa M, Hylind LM, Romans KE, Booker SV, Giardiello FM. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology 2002;122: 641-5.
51. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342: 1946-52.
52. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-90.
53. Hida T, Kozaki K, Ito H, Miyaishi O, Tatematsu Y, Suzuki T, et al. Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents. Clin Cancer Res 2002;8:2443-7.